Molecular Partners - MOLN Income before deduction of interest, taxes and amortization

Brandmark of molecularpartners.com (MOLN)

Growth for Molecular Partners AG is driven by the success of the DARPin platform in radiopharmaceuticals and payments from pharma behemoths. Monitoring EBITDA_Co, which accounts for the outsourcing of production to third-party contractors, allows for the identification of cash flow anomalies. The value of 0.00 reflects the baseline level of the metric. Promising developments in targeted oncology and ophthalmology create an effective alternative to standard antibodies, stimulating business growth.

MOLN: molecularpartners.com Profit before payment of interest, taxes and amortization 11/23/2025 - 11/11/2026

Molecular Partners AG - analytical breakdowns and key metrics (MOLN)

- market value and analyst target forecast:
Market Price Molecular Partners Ltd|MOLN - Consensus Target
- issuer market value details:
Market Value Molecular Partners|MOLN - Total Company Value
- book capitalization information:
Share Book Value Molecular Partners|MOLN - Company Book Value|Market Value to Book Value Ratio molecularpartners.com|MOLN - Company Total Assets
- debt level and financial liquidity data:
Total Debt to Capital Molecular Partners AG|MOLN - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio molecularpartners.com|MOLN - Company Aggregate Debts|Debts to Book Capitalization Ratio Molecular Partners|MOLN - Company Long-Term Debt|Short-Term Debt Molecular Partners|Intermediate Coverage Ratio molecularpartners.com
- earnings and valuation multiples information:
MOLN - Company Net Income|Future Profit Molecular Partners AG|MOLN - Price to Earnings Ratio|Market Cap to Projected Earnings Molecular Partners Ltd|MOLN - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Molecular Partners|MOLN - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Molecular Partners|MOLN - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months molecularpartners.com|MOLN - Earnings growth in current year|Expected net earnings per share growth next year Molecular Partners AG
Summary company analytics:Molecular Partners Ltd, MOLN
Original product of Molecular Partners Ltd

Absolute operating profit measures cash flow before taxes and interest, allowing for an assessment of the core business's actual efficiency without the influence of debt load. By analyzing absolute EBITDA trends, an investor determines the financial stability of Molecular Partners AG (MOLN), where profit growth confirms the successful integration of ESG standards and ethical oncology drug development methods into the overall business model.

Competitors of Molecular Partners AG (MOLN)

Geron Bio (GERN) - Profit before interest, taxes and amortization|NBTX: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization BCYC (bicycletherapeutics.com)|CytomX Therapeutics, Inc. (CTMX) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization CATX (Perspective Therapeutics, Inc.)|Profit before payment of interest, taxes and amortization Genelux Corp.|Profit before payment of interest, taxes and amortization ONCY|Operating profit EBITDA LSTA|Operating profit EBITDA moleculin.com (MBRX)|Galera Therapeutics, Inc. - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization MTEM (Molecular Templates Inc)